Almost daily, we hear about the purported benefits, as well as risks, associated with the use of cannabis and cannabis-derived compounds such as CBD. What does the research actually show? This webinar will provide an overview of research outcomes regarding both therapeutic and other benefits of cannabis/CBD, including toxicity concerns, in both healthy and patient populations. The panel will also discuss CBD safety questions FDA is currently considering, new technologies to deliver cannabis to the body more efficiently for therapeutic and adult-use purposes, and an update on federal efforts to expand cannabis research.

Get Access

  • +$100 for nonmembers

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.


Claire Beggs, Senior Director, Regulatory Affairs, GW Pharmaceuticals
Ziva Cooper, Research Director, UCLA Cannabis Research Initiative
Aidan Hampson, Special Content Expert-Cannabis, National Institute on Drug Abuse
Moderated by Christina Markus, Partner, King & Spalding LLP

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.

Related Content